tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Target trial emulations for tirzepatide,
Description
For pancreatitis from other causes, individualized medical advice is needed, but extreme caution with alcohol is warranted given the potential association between GLP-1 receptor agonists and pancreatitis risk

Patients should report any suspected side effects via the MHRA Yellow Card scheme (yellowcard

Not hazy

97 , E1023E1031 (2012)

Individual susceptibility varies based on factors including dosage, concurrent medications, and underlying health conditions